|  |  |  |  |
| --- | --- | --- | --- |
|  |  | OptimiseRx | October 2021  Issue 03 |
|  |  | Hampshire and Isle of Wight ICS  Southampton Area Hampshire, Southampton and Isle of Wight CCG | |
| Contents  \_\_  Highlights from this quarter  Any good news about performance over the last quarter  \_\_  Message in Focus  Message(s) that need some education around or update on progress on them e.g. ACB or PINCER set  \_\_  OptimiseRx Top Tip  Info that may improve use of ORx for example rejection reasons being optional |  | There has been an excellent acceptance rate of cost and formulary messages and a good acceptance rate for best practice messages. Message in Focus **Using Standardised Strengths of Unlicensed Liquid Medicines in Children-some reminders**  A joint statement from the Neonatal and Paediatric Pharmacists' Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH).  Recommendation:  NPPG and RCPCH strongly recommend that when children require unlicensed liquid medications, they should receive the RCPCH- and NPPG- recommended strength, where one exists. There are currently 17 such recommended strengths, 16 of which are published in relevant drug monographs of the BNF for Children. Standardising the prescribed strengths of these medicines, will reduce the risk of errors being made in the doses given to children and prevent hospitalisation from accidental under- and overdoses.  The most recent version is available at the links below   * [Choosing an oral liquid for a child – NPPG](http://nppg.org.uk/choosing-an-oral-liquid-for-a-child/) * [Standardised strengths which should be prescribed](http://nppg.org.uk/wp-content/uploads/2020/04/NPPG-Position-Statement-18-01-V5-April-2020.pdf) | |
|  |  |  | |

|  |  |  |  |
| --- | --- | --- | --- |
| **OptimiseRx – Hampshire & IoW ICS** |  |  | |
| **OptimiseRx Top Tip**  Adding a rejection reason and making it informative  I.e. it would be good to understand why you choose to reject a message.  Therefore, please do not try to close the message but select **Reject (EMIS)** or **Overrule (SystmOne)** and provide details  E.g. a clinical indication or where the prescription request has come from in the reasons box  **Best practice messages:**  **Lymecycline or doxycycline** are recommended first-line for the treatment of acne.  NICE CKS (Jun 2021) does not recommend the use of minocycline for the treatment of acne due to an increased risk of serious adverse events. NICE (NG198, Jun 2021) recommends lymecycline 408mg daily or doxycycline 100mg daily for the treatment of acne vulgaris, where oral antibiotics are indicated. NHS England (Jun 2019) and AWMSG (May 2021) support the deprescribing of minocycline for acne.  **Co-cyprindiol i**s not recommended in acne unless treatment with systemic antibiotics and topical therapy has failed. This is supported by NICE CKS (Jun 2021) and has been reaffirmed by the MHRA Drug Safety Update (Dec 2014). For the first-line treatment of severe acne the NICE CKS guideline recommends a combination of oral antibiotics and topical treatment (except topical antibiotics).    New cost messages:  Trazodone 50mg or 100mg tablets Trazodone 50mg or 100mg capsules    Olanzapine oral lyophillsates SF  Olanzapine orodispersible tablet  Loperamide 25mg/5ml oral suspension  Loperamide 25mg/5ml oral solution  Vagifem® tablets  Vagirux® tablets  Levomepromazine 6mg tablets (any)  Levomepromazine 25mg tablets (quarter)  Reminder: please do not prescribe Simple eye ointment 4g £53.28 (NHSDT October2021). There are other more cost cost-effective alternatives. |  | | RESOURCES **FDB OptimiseRx 2020 and 2021 Lunchtime Learning Webinars:** [**AVAILABLE TO VIEW ON-DEMAND**](https://interactive.fdbhealth.com/optimiserx_lunchtimelearnings_ondemand)  **2020** [**How OptimiseRx supports your PCN’s and Practices**](https://www.bigmarker.com/first-databank-uk/How-can-OptimiseRx-support-your-PCN-and-Practices-36b1fb7ddfdbf21bd8c8b853)  **2021**  [**Overview of OptimiseRx: For New Starters e.g. GP Registrars/ NMPs**](https://www.bigmarker.com/first-databank-uk/Introduction-to-FDB-OptimiseRx)  [**How OptimiseRx can support your job role within PCNs and Practices EMIS users**](https://www.bigmarker.com/first-databank-uk/Insert-title-EMIS-users-only-3fe06a5225ddab7ffad89aa4)  [**How OptimiseRx can support your job role within PCNs and Practices SystmOne users**](https://www.bigmarker.com/first-databank-uk/How-OptimiseRx-can-support-your-job-role-within-PCNs-and-practices-TPP-SystmOne-users-only)  [**Backstage with our OptimiseRx Clinical Content Team**](https://www.bigmarker.com/first-databank-uk/Backstage-with-our-OptimiseRx-Clinical-Content-Team)  **[Unpacking your questions: How FDB primary care solutions can help meet your priorities](https://www.bigmarker.com/first-databank-uk/ORx-LL-Block-3-Webinar-2)**  **Hampshire, Southampton & Isle of Wight CCG – New Website The new website is now live, following the merger, on the 1 April, of Southampton, Fareham and Gosport, North Hampshire, West Hampshire and South East Hampshire CCGs.**  **Click** [**HERE**](https://gp-portal.westhampshireccg.nhs.uk/) **to see the CCG’s Medicines Optimisation landing page and links to SCGs and other guidance** |

Trigger products Donepezil 5mg and Donezepil 10mg orodispersibole tablets have been discontinued.

Please consider prescribing Donezepil 5mg sand Donezepil 10mg sugar-free orodispersible tablets:

**13985—Donepezil 5mg orodispersible tablets** (discontinued; brands, generic): consider prescribing donepezil

5mg sugar-free orodispersible tablets for patients with swallowing difficulties

**13986—Donepezil 10mg orodispersible tablets** (discontinued; brands, generic): consider prescribing donepezil

10mg sugar-free orodispersible tablets for patients with swallowing difficulties

Prescribing ciprofloxacin 2mg/ml 0.25ml unit dose preservative-free ear drops (licensed) instead of ciprofloxacin

0.3% eardrops (unlicensed) is best practice. The GMC (2013) recommends prescribing licensed medicines, where available, in preference to unlicensed medicines; licensed medicines are more cost-effective and associated with less risk than special order products. Refer to product literature for dosing information. Advise patient of preparation change and dosing instructions.

**25754—Ciprofloxacin 0.3% ear drops (unlicensed)**: consider prescribing ciprofloxacin 2mg/ml 0.25ml unit dose

preservative-free eardrops (licensed)

**24487—Progestogens:** not recommended in women without a uterus

See [OptimiseRx Bulletin](file:///C:\Users\vdamani\AppData\Local\Microsoft\Windows\INetCache\Content.Outlook\OP8H6KJ4\OptimiseRx_Content_Bulletin_05072021_82.pdf%20(fdbhealth.co.uk)) here for details. Progestogens are not usually indicated following a total hysterectomy, or where the uterus is absent, as there is no additional benefit compared to oestrogens alone. Message Details: is supported by NICE (NG23, Dec 2019)